QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients Original Research Article

Background Sudden unexplained death in psychiatric patients may be due to drug-induced arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram is a predictive marker. We estimated the point prevalence of QTc lengthening in psychiatric patients and the effects of various psychotropic drugs. Methods Electrocardiograms were obtained from 101 healthy reference individuals and 495 psychiatric patients in various inpatient and community settings and were analysed with a previously validated digitiser technique. Patients with and without QTc lengthening, QTc dispersion, and T-wave abnormality were compared by logistic regression to calculate odds ratios for predictive variables. Findings Abnormal QTc waas defined from the healthy reference group as more than 456 ms and was present in 8% (40 of 495) of patients. Age over 65 years (odds ratio 3·0 [95% CI 1·1–8·3]), use of tricyclic antidepressants (4·4 [1·6–12·1]), thioridazine (5·4 [2·0–13·7]), and droperidol (6·7 [1·8–24·8]) were robust predictors of QTc lengthening, as was antipsychotic dose (high dose 5·3 [1·2–24·4]; very high dose 8·2 [1·5–43·6]). Abnormal QT dispersion or Twave abnormalities were not significantly associated with antipsychotic treatment, but were associated with lithium therapy. Interpretation Antipsychotic drugs cause QTc lengthening in a dose-related manner. Risks are substantially higher for thioridazine and droperidol. These drugs may therefore confer an increased risk of drug-induced arrhythmia.